Summary & Overview

HCPCS Q5159: Denosumab-dssb (ospomyv/xbryk) Injection, 1 mg

HCPCS Level II code Q5159 identifies the biosimilar denosumab product denosumab-dssb (ospomyv/xbryk) billed per 1 mg for injectable administration. As a biologic biosimilar to denosumab, this product is used in clinical settings where monoclonal antibody therapies are indicated; accurate coding matters for drug inventory, administration tracking, and payer reimbursement workflows nationwide. Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code’s clinical and billing context, typical sites of service, and what to expect in payer coverage considerations. The publication outlines benchmarks and policy-relevant items typically tracked for biosimilar injectable products, highlights common billing modifiers and service-line implications (where available), and summarizes areas where clinicians and billing teams should confirm payer-specific rules and prior authorization requirements. Data not available in the input is noted where applicable. This national-level summary is intended to orient billing professionals, revenue integrity teams, and clinicians to the primary meaning and administrative implications of HCPCS Level II code Q5159.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareQ5159HCPCS Level IIdenosumabbiosimilarinjectablebiologicinfusiondrug-administration

Billing Code Overview

HCPCS Level II code Q5159 describes an injection formulation of denosumab-dssb (ospomyv/xbryk), biosimilar, measured per 1 mg. This code represents the billed service for administration of the specified biosimilar denosumab product.

Service type: Injectable biologic/monoclonal antibody administration
Typical site of service: Outpatient infusion clinic, physician office, or other ambulatory care setting where injectable biologics are administered

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A typical patient is a postmenopausal woman or an adult with osteoporosis or bone loss related to metastatic bone disease who presents for subcutaneous injection of a denosumab biosimilar, billed as Q5159. The medication is administered in an outpatient infusion or injection suite, specialty clinic (endocrinology, oncology, rheumatology), or physician office. The clinical workflow includes verification of indication and recent labs (calcium, creatinine), review of allergy and medication history, patient counseling on risks (hypocalcemia, infection), obtaining informed consent, preparation of the prefilled syringe, performing a subcutaneous injection (typically upper arm, thigh, or abdomen), monitoring for immediate adverse reaction for 15–30 minutes, documentation of lot number and site, and scheduling of follow-up dosing (usually every 6 months for osteoporosis dosing regimens). Typical supportive services include medication administration billing, vital signs, and patient education on calcium and vitamin D supplementation. The procedure is commonly provided by endocrinologists, oncologists, rheumatologists, primary care physicians, and nurse practitioners or physician assistants under supervision.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier (no specific indicator)	Use when no applicable modifier applies and billing per usual rules.
`22`	Increased procedural services	Use when work required is substantially greater than typical (document justification and time/complexity).
`52`	Reduced services	Use when service is partially reduced or not completed as described by the CPT/HCPCS; document reason.
`53`	Discontinued procedure	Use when the injection appointment was started but discontinued due to patient condition or adverse event.
`SH`	Diagnostic Services Provided in Whole or in Part by a SNF	Use when the service was provided in a Skilled Nursing Facility setting under `SH` semantics.
`24`	Unrelated evaluation and management service by the same physician during a postoperative period	Use if an unrelated E/M is provided same day as the injection during a global period.
`25`	Significant, separately identifiable E/M service on the same day	Use when a distinct E/M visit is performed and documented on the same day as the injection.
`59`	Distinct procedural service	Use to indicate a separate, distinct service from other procedures billed on the same date.
`76`	Repeat procedure or service by same physician	Use when the injection or administration is repeated later the same day by the same provider.
`77`	Repeat procedure by another physician	Use when another provider repeats the procedure the same day.
`LT`	Left side	Use when laterality is required to specify injection site on the left.
`RT`	Right side	Use when laterality is required to specify injection site on the right.
`XE`	Separate encounter, a distinct encounter	Use when modifier XE (if accepted) is required to show a distinct encounter from other services.
`XU`	Unusual non-overlapping service	Use when service is distinct and does not overlap with other services (if payer accepts X modifiers).

Taxonomy Code	Specialty	Notes
`207RE0101X`	Internal Medicine	Primary care physicians often manage osteoporosis and order/administer denosumab.
`207RC0000X`	Endocrinology	Endocrinologists commonly prescribe and oversee treatment for osteoporosis and metabolic bone disease.
`207RH0002X`	Rheumatology	Rheumatologists manage inflammatory bone loss and osteoporosis in chronic autoimmune disease.
`207L00000X`	Oncology	Oncologists administer denosumab for prevention of skeletal-related events in metastatic bone disease.
`363L00000X`	Nurse Practitioner	Nurse practitioners frequently perform medication administration and clinic-based injections.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`M81.0`	Age-related osteoporosis without current pathological fracture	Common indication for denosumab to reduce fracture risk in postmenopausal osteoporosis.
`M80.08XA`	Age-related osteoporosis with current pathological fracture, other site, initial encounter for fracture	Denosumab may be used in patients with osteoporosis who have sustained fractures.
`M84.50XA`	Pathological fracture, unspecified site, initial encounter for fracture	Used when pathological fractures occur due to bone fragility; denosumab can be part of management.
`C79.51`	Secondary malignant neoplasm of bone	Denosumab is used to prevent skeletal-related events in patients with bone metastases.
`M89.9`	Disorder of bone, unspecified	Used when a specific bone disorder is diagnosed and denosumab is considered.
`Z79.51`	Long term (current) use of denosumab	Applicable for documenting ongoing therapy with denosumab biosimilar in the medication list.
`E83.50`	Disorder of calcium metabolism, unspecified	Lab abnormalities (hypocalcemia risk) are relevant to monitoring before and after denosumab administration.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Commonly used to report the act of administering a subcutaneous injection of denosumab when applicable for payer rules.
`96401`	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic (single or initial substance/drug)	Used in oncology settings when injected biologic administration is billed under chemotherapy administration rules if payer requires.
`99401`	Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (15 minutes)	Used when separate documented counseling on bone health and risk reduction is provided at the visit.
`99024`	Postoperative follow-up visit, normally included in global service, related to the original procedure	Used if follow-up related to administration is billed outside a global period per payer rules.
`99070`	Supplies and materials (eg, gloves, syringes) provided by the physician over and above those usually included with the office visit or procedure	Used when additional disposable supplies specific to medication administration are separately billable per payer policy.